'Effects of the angiotensin-converting enzyme inhibitor perindopril on endothelial and platelet function in essential hypertension'.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Platelets

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/09537109876474PMID 16793724
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A lack of effect of captopril on platelet aggregation in patients with congestive heart failure

  2004cited by this paper
• Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertension.

  1998cited by this paper
• D118: Effect of perindopril and of nitrendipine on plasma fibrinogen in overweight hypertensive patients

  1997cited by this paper
• Metabolic effects of long-term treatments with nifedipine-retard and captopril in young hypertensive patients.

  1997cited by this paper
• ACE inhibitor effects on platelet function in stages I-II hypertension.

  1997cited by this paper
• A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose-Response Study Group.

  1996cited by this paper
• Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients.

  1996cited by this paper
• Platelet and leukocyte activation after myocardial infarction. Influence of enalapril.

  1995cited by this paper
• Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients.

  1995cited by this paper
• Metabolic effects of antihypertensive drugs

  1995cited by this paper
• Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.

  1994cited by this paper
• Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study

  1993cited by this paper
• Potential Use of ACE Inhibitors After Acute Myocardial Infarction

  1989cited by this paper
• General pharmacology of ramipril.

  1988cited by this paper
• Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation.

  1988cited by this paper
• Epidemiological characteristics of platelet aggregability.

  1985cited by this paper
• The contact phase of blood coagulation and renin activation in essential hypertension before and after captopril.

  1984cited by this paper

• Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review

  2019cites this paper
• Acquired Disorders of Platelet Function

  2013cites this paper
• Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculated using the Framingham equation.

  2007cites this paper
• Fibrinogen: a predictor of vascular disease.

  2007cites this paper
• The Relationship Between Circulating Fibrinogen and Lipoprotein (a) Levels in Patients With Primary Dyslipidemia

  2007cites this paper
• CHAPTER 58 – Acquired Disorders of Platelet Function

  2007cites this paper
• Effect of Antihypertensive Treatment on PlasmaFibrinogen and Serum HDL Levelsin Patients with Essential Hypertension

  2005cites this paper
• The effects of lipid-regulating therapy on haemostatic parameters.

  2003cites this paper
• The effects of antihypertensive therapy on haemostatic parameters.

  2003cites this paper
• Effect of the angiotensin-converting enzyme inhibitor perindopril on haemostasis in essential hypertension

  2000cites this paper
• Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia.

  1999cites this paper
• Platelet function and lipid-lowering interventions.

  1999cites this paper